/PRNewswire/ Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture.
/PRNewswire/ Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture.
/PRNewswire/ Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture.
®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination
1, announced today that it has become a category-exclusive member of the Emergency Nurses Association (ENA
™) Corporate Engagement Council.
The ENA Corporate Engagement Council (CEC) is designed to support innovation, advances in emergency nursing education, research and advocacy. Together, Magnolia Medical leadership and ENA leaders from the association team, board of directors and key ENA influencers – a mix of businesses, educators and hospitals – will create new opportunities to educate the emergency nursing profession on the most recent advancements in blood culture best practices and sepsis testing accuracy. We are thrilled to partner with the Emergency Nurses Association as an active member of its Corporate Engagement Council, said Greg Bullington, CEO of Magnolia Medical. We look forward to working closely with ENA leadership to further improve patient safety and dr
®, the only FDA-cleared device platform indicated to reduce blood culture contamination
1 – today announced that unprecedented Steripath clinical study results were presented to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB).
Lucy S. Tompkins, MD, Ph.D., a professor and infectious diseases, microbiology and epidemiology expert at Stanford Health Care, presented Steripath
® Gen2 Initial Specimen Diversion Device
® (ISDD
®) phase-one study results at the PACCARB meeting in Washington, DC demonstrating unmatched reductions to blood culture contamination and false-positive central line-associated bloodstream infection (CLABSI) rates. What was even more clinically significant is that a 0.0% contamination rate and 0.0% false-positive CLABSI rate were maintained across over 11,000 blood cultures when Steripath was used throughout the course of the 10-month total trial period, continued Dr. Tompkins